AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01841411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement,it is a derivative of the natural amino acid cysteine, from which it differs by virtue of the introduction of an acetyl group on the nitrogen atom of the amino terminal.It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has shown good properties in terms of combating bacterial infections. In particular, it has been observed that NAC presents good activity in terms of inhibiting bacterial adhesion and in dissolving the biofilm matrix.
Study NCT00625833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet once a day dosing for 10 weeks.
Study NCT00625833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-Reboxetine
Description: Oral tablet once a day dosing for 10 weeks.
Study NCT03223480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided gastrojejunstomy
Description: As listed in the arms description
Study NCT02800408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain high-BCX maize
Description: The whole grain orange maize will be milled and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
Study NCT02800408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined grain high-BCX maize
Description: The refined grain orange maize will be degermed, milled, and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
Study NCT02800408 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Whole grain white maize
Description: The whole grain white maize will be milled and prepared into muffins to be consumed daily. Muffins will contain minimal beta-cryptoxanthin, matched for dry maize weight.
Study NCT02953639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basmisanil
Description: Participants received either 80 milligrams (mg) or 240 mg of Basmisanil, as per the dosing schedules described above.
Study NCT02953639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received matching Placebo to Basmisanil, as per the dosing schedules described above.
Study NCT00906893 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18F]-FMISO PET-CT
Description: pretherapy(\[18F\]-FMISO) positon emission tomography-computed tomography. Different acquisition protocols will be tested and a wild panel of quantification parameters issued from published studies and original ones developed by our team enable to describe \[18F\]-FMISO uptake will be used.
Study NCT00349167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR-104
Study NCT00349167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00349167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT04114292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tauroursoursodeoxycholic acid, brand name Tudcabil
Description: Dosed in capsules containing 250 or 500mg of TUDCA for a total dose of 1.75-2g/day
Study NCT03449498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qualitative functional therapy
Description: Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Six functional activities focusing on lower limbs and trunk are performed: walking, stair climbing, balance, transfers, trunk control, and Wii (combination of functional activities in sitting and/or standing). A group of clinical experts composes a set of exercises for each of these activities, however individual adaptations according to the needs and abilities of the child can be still be done. Quality of movement (alignment, weightshift, dissociation, coordination and stability) is hereby very important. The theme 'circus' is used to enhance the motivation of the children.
Study NCT03449498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional therapy
Description: Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Goals are set with the parents and the children. During the camp children work on obtaining these goals in a exclusively functional way.
Study NCT02956954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (Agalsidase alpha (Replagal®))
Description: Patient treated with Enzyme replacement therapy as usual (Agalsidase alpha (Replagal®)). The treatment is prescribed in routine and not specially for the protocol
Study NCT02956954 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging will be assessed every 6 months during 2 years
Study NCT02956954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging will be assessed every 6 months during 2 years
Study NCT00907348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LR-CHOP21
Description: FIRST DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 5 mg/day D1-D14~SECOND DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1;Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 10 mg/day D1-D14~THIRD DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 15 mg/day D1-D14~FOURTH DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 20 mg/day D1-D14 Repeated every 21 days
Study NCT00883662 — intervention group
Intervention type: DRUG
Intervention: Levonorgestrel (Mirena, BAY86-5028)
Description: Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications
Study NCT01467843 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: The Cognitive Behavioral Therapy Intervention will be delivered during 8 weekly classes each lasting 2 hours. The classes will be held at a conveniently located Group Health Facility.
Study NCT01467843 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction
Description: The Mindfulness Based Stress Reduction Classes will be delivered in 8 weekly classes each lasting 2 hours.
Study NCT01262378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal plastic surgery
Description: Surgery for ABDOMINAL SUBCUTANEOUS FAT
Study NCT01262378 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: abdominal plastic surgery
Description: Surgery for ABDOMINAL SUBCUTANEOUS FAT
Study NCT00402649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Description: Inactivated influenza A/H5N1 vaccine administered via intramuscular (IM) injection; dosage 45-mcg.
Study NCT01040351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided aspiration of hydrosalpingeal fluid
Description: Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
Study NCT00677651 — intervention group
Intervention type: PROCEDURE
Intervention: Adipose Biopsy
Description: Adipose tissue will be sampled from the abdomen and buttock
Study NCT00677651 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: Blood will be sampled from an IV line
Study NCT00677651 — intervention group
Intervention type: RADIATION
Intervention: CT Scan
Description: Single image at the level of the liver
Study NCT00677651 — intervention group
Intervention type: RADIATION
Intervention: DEXA
Description: Whole body scan
Study NCT01432249 — intervention group
Intervention type: DRUG
Intervention: Enbrel group
Description: will be decided by treating physicians
Study NCT01999465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard NMES device
Description: Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~* Rate(35 Hz)~* Width (300 us)~* Ch1 Ramp+ (2 seconds)~* On Time 1 (10 seconds)~* Ch1 Ramp - (2 seconds)
Study NCT01999465 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NMES device
Description: Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~* Rate(35 Hz)~* Width (48 us)~* Ch1 Ramp+ (0 seconds)~* On Time 1 (0 seconds)~* Ch1 Ramp - (0 seconds)
Study NCT04798599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring and teleorientation
Description: Teleservice will be performed through a digital platform (Video for Health - V4H). The service will consist of: a) recognition of the condition identified in the pandemic period, including updates on medical history, current oral health condition, search for dental care in other units, need for referral, change of hygiene habits, b) realization of diet guidance, hygiene and other necessary habits, made from a situational recognition of such habits, c) targeting the needs presented, in which individualized counselling will be given seeking to meet the demand presented by that family nucleus. A dental form developed on the digital platform Google Forms will serve as a guide for the performance of the service and where the collected data will be formally recorded. The guidelines, although individualized for the needs of each child, will follow a pre-defined and standardized structure and based on the best evidence available in the subject.
Study NCT04798599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group - Waiting list
Description: No intervention (at least, until the time frame for outcome assessment)
Study NCT01572116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine with Epinephrine+ Normal saline
Description: PDL injection of 0/4 ml of lidocaine %2 with epinephrine,and Normal saline
Study NCT01572116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine with Epinephrine + sufentanil
Description: PDL injection of 0/4 ml lidocaine with epinephrine and0/4 ml sufentanil ( 0/04 μg)
Study NCT04053868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL
Description: Electronic Cigarette
Study NCT04053868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco
Description: Tobacco Cigarette
Study NCT02281643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 200mg oral doxycycline will be administered immediately (early) in the experimental arm or delayed in the comparator arm
Study NCT02281643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 200mg oral doxycycline will be administered immediately (early) in the experimental arm or delayed in the comparator arm
Study NCT00760019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salsalate
Description: 1.5 grams orally 3 times daily
Study NCT00760019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study NCT00366275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy, in vivo purging and autrotransplant
Description: 2-4 courses every 3 weeks with rituximab 375 mg/m\^2 on day 1, vincristine 1.4 mg/m\^2 on day 2 and cyclophosphamide 400 mg/m\^2 on days 2-6. Courses were started if granulocytes >1.5 · 10\^9/l. The phase of peripheral blood stem cells (PBSC) mobilization coupled rituximab 375 mg/m\^2 on days 1 and 9 with high-dose cytarabine (AraC) 2 g/m\^2 every 12 hours on days 2 and 3. Granulocyte colony-stimulating factor (G-CSF)(5 mcg/kg/day subcutaneously) was administered from day 6. High-dose chemotherapy with autotransplant consisted of BEAM \[carmustine (BCNU), etoposide, Cytarabine (AraC), melphalan\] followed by the infusion of in vivo purged peripheral blood stem cells (PBSC) + 2 consolidation doses of rituximab 375 mg/m\^2 on days +14 and +21 after autotransplant.
Study NCT01349868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT005 MDI
Description: PT005 MDI taken as two inhalations
Study NCT01349868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
Description: Taken as 1 capsule. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
Study NCT01349868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate 24 μg (Foradil® Aerolizer®)
Description: Taken as 2 capsules. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
Study NCT01349868 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Matching placebo to PT005 MDI taken as two inhalations
Study NCT04427007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moisture Management Liner
Description: A prototype liner designed to reduce and/or remove moisture and heat that builds up on the limb.
Study NCT04427007 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ICE Socket Cooling System
Description: The ICE Socket Cooling System is a battery-powered cooling device for lower-limb amputees.
Study NCT04427007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICE Socket Cooling System
Description: The ICE Socket Cooling System is a battery-powered cooling device for lower-limb amputees.
Study NCT01786200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT01786200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT03677830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Scheduled intravenous acetaminophen for post-operative pain to minimize opiate exposure.
Study NCT03677830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous saline will be administered at appropriate volume and schedule for control group as a placebo.
Study NCT03370536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioInsight ECGI Mapping System
Description: The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.
Study NCT03370536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation
Description: Empiric ablation (CFAE or linear ablation) is not permitted
Study NCT03370536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: Progressive doses of Ibutilide administered (0.25mg, then 0.25mg, then 0.5mg)
Study NCT02791984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluid challenge with 250 ml of Ringer Lactate
Description: Fluid challenge with 250 ml of Ringer Lactate over less than 2 minutes, intra-venous, help by a syringe of 50 ml.~Measure of peak velocity before and after the fluid challenge
Study NCT00522145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL647
Description: Daily dosing as a single oral agent at a dose of 300 mg supplied as 50-mg tablets
Study NCT04096209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autograft mixed with xenograft bone
Description: Eligible patients will be randomized in equal proportions between control group (immediate implant placement without bone grafts in the jumping gap) and study group (immediate implant placement with a mixture of Xenograft and autogenous bone placed in the jumping gap).~All patients will be evaluated by proper history taking and thorough clinical and radio graphical examination and assessed according to the inclusion and exclusion criteria.~Patients of both groups will be subjected to Cone beam Computed tomography (CBCT).~Primary impression will be taken, a study model will then be poured and then waxing up will be performed.~Patients will be instructed to rinse with chlorhexidine 0.1% mouthwash. Articaine 4% (1:100,000) local anesthesia will be given to the patient. Atraumatic extraction of the tooth or remaining root using No. 15c lancet and periotome
Study NCT01370720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Recoclix
Description: tablets; 200 mg PEA+20 mg polydatin; 2 tablets/day; 12 weeks
Study NCT01370720 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets, 2tablets/day, 12 weeks
Study NCT01465100 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preparative Radiation Therapy
Description: Subjects will undergo CT-based simulation and treatment planning for radiation therapy. Once a suitable hepatocyte donor is found and the cell count and viability is acceptable for transplantation, patients will receive Intensity-Modulated Radiation Therapy (IMRT) in one fraction(10 Gy)to the right lobe of the liver (but not exceeding 50% of the liver mass).
Study NCT01465100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatocyte Transplant
Description: Transplantation of hepatocytes into the liver will be through the portal vein, either accessed transhepatically, or by umbilical vein. After cell transplantation, measures will be taken to provide chronic access to the portal venous circulation system. If chronic access is achieved, patients will be seen in the PCTRC once a week to assess the site.~Hepatocytes from more than one donor may be required to provide sufficient numbers of cells for transplantation to correct the disease process and to optimize Phe tolerance. Hepatocytes will be infused until the goal number of hepatocytes is infused. If viable hepatocytes remain after the goal number has been infused, the remaining cells will also be infused, as tolerated by the patient.
Study NCT01465100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppression
Description: Following transplantation, patients will be treated with conventional immune suppression, as is used following whole organ liver transplantation. Patients will be followed as routinely performed following organ transplantation and also followed as would normally be performed for their PKU.
Study NCT01465100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liver Evaluation
Description: Prior to the hepatocyte transplant subjects will undergo a liver evaluation which is standard for all patients who have whole organ transplants at Children's Hospital of Pittsburgh of UPMC. The evaluation includes immunosuppression medication education, psychological assessment, bloodwork to assess blood count, blood and tissue type, blood chemistries, immune system function and certain infectious diseases, EKG, chest x-ray, and abdominal ultrasound to assess blood flow to the blood vessels in the liver. A liver biopsy may be performed if, in the clinical judgment of the investigators, the subject shows clinical signs of liver failure, or is at increased risk for liver fibrosis.
Study NCT01465100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuro-psychological Assessment
Description: Subjects will undergo a repeat neuropsychological assessment at 6, 12 and 24 months post-transplant (Visits 4 and 6 and the End of Study Visit) which will be compared to results obtained pre-transplant to determine whether an improvement in assessment scoring is associated with the transplant procedure.
Study NCT01465100 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole body Phe oxidation testing
Description: Patient will again be asked to not eat or drink for at least four hours prior to testing. Isotopic monitoring of whole body Phe oxidation will be performed pre-transplant and at every follow-up visit following the final hepatocyte infusion. An additional Phe oxidation test may also be completed in the event of suspected graft rejection.
Study NCT01465100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Biopsy
Description: Liver biopsies will be performed at 3 and 12 months post-transplant to assess for the presence of donor hepatocytes, and may be completed in the event of suspected graft rejection.
Study NCT04628637 — intervention group
Intervention type: OTHER
Intervention: Serum protein level analysis
Description: Serum GRP78 levels of the subjects were measured through a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Human Glucose Regulated Protein 78 (GRP78) ELISA Kit, Sun Long, SL2048Hu, China), as per the manufacturer's protocol. The detection rate of this kit is 16 pg/mL.
Study NCT03027362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) and medication
Description: Sixteen sessions over 14 weeks.
Study NCT03027362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation and medication
Study NCT04090008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRP gel
Description: The PRP gel is applied on the ulcer twice per week
Study NCT04090008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline dressing
Description: Normal saline is used for dressing of the ulcer twice a week
Study NCT02281370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: White to off white bi-convex round tablets containing eltrombopag 50 mg for oral administration